Syndax Pharmaceuticals earnings date
Syndax Pharmaceuticals (1T3) Q3 2026 Earnings Report
DE:1T3 Q3 2026 EPS Results
- Actual EPS
- -EUR 0.50
- Consensus EPS
- -EUR 0.46
- Beat/Miss
- Missed by -EUR 0.04
- One Year Ago EPS
- -EUR 0.64
DE:1T3 Q3 2026 Revenue Results
- Actual Revenue
- EUR 75.97M
- Expected Revenue
- EUR 74.21M
- Beat/Miss
- Beat by +EUR 1.75M
- YoY Revenue Growth
- +81.59%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/02/2026
- Time
- After Close
- Conference Call
- Monday, November 2, 2026
Syndax Pharmaceuticals's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, supported by 82% year-over-year total revenue growth, sustained double-digit Revuforj growth, expanding patient starts and account adoption, rising Niktimvo revenue and collaboration income, a strong cash position, and multiple clinical and pipeline catalysts. The principal challenges were the temporary transplant-related treatment pauses, prior-quarter market volatility, active competition and delayed timing for certain clinical readouts. Highlights significantly outweighed the lowlights.
Management expects Revuforj could exceed $2 billion in peak annual net revenue in the U.S. alone with anticipated front-line indications, while Niktimvo collaboration revenue is annualizing at over $90 million and is expected to keep growing; the Niktimvo margin contribution is expected to be in the low-to-mid-30% range, and total R&D plus SG&A expenses for 2026 remain approximately $400 million, excluding $50 million in estimated noncash stock compensation expense. Management expects Revuforj data in relapsed/refractory NUP98-rearranged acute leukemia in the fourth quarter, both pipeline molecules to be in the clinic next year, an IND for 4321 by the end of 2026, an IND for 62122 next year, a Phase I/II revumenib trial in MF to initiate in the fourth quarter of 2026 with initial data anticipated in the second half of next year, axatilimab Phase II combination top line results in the first quarter of 2027 and Phase 3 combination top line results in early 2028, and the first assessment of 4321 monotherapy in lung cancer in early 2028; over time, up to 70% to 80% of KMT2A patients are expected to return to therapy for 1 to 2 years, while response duration is expected to be in the 6 to 12 month range for patients who receive a response.
- Strong Third-Quarter Revenue GrowthTotal revenue reached $83.3 million in the third quarter of 2026, up 82% year-over-year. Revenue included $60.7 million from Revuforj net revenue and $22.6 million of Niktimvo collaboration revenue. Management said revenue from both medicines is expected to continue growing and advancing the company toward profitability.
- Revuforj Delivered Sustained Commercial GrowthRevuforj net revenue totaled $60.7 million, up 90% year-over-year and 11% quarter-over-quarter. The company achieved its seventh consecutive quarter of double-digit quarter-over-quarter Revuforj net revenue growth, driven by a 20% increase in new patients and an increasing number of patients resuming therapy after stem cell transplant.
- Revuforj Maintained Menin-Inhibitor Market LeadershipManagement expects Revuforj to account for more than 80% of menin-inhibitor class revenue this quarter. Claims and prescription data showed Revuforj had the dominant share of new patients across all age groups, including the predominantly NPM1 Medicare population. The company said Revuforj has been used commercially by nearly 2,000 patients, with hundreds more treated in clinical trials.
- Revuforj Prescription and New-Patient Metrics IncreasedTotal Revuforj prescriptions were approximately 1,700, up 13% quarter-over-quarter and double the level of the prior-year quarter. Approximately 300 new patients started therapy, up approximately 20% quarter-over-quarter, with growth in both NPM1 and KMT2A patients.
- Growth in NPM1 Commercial AdoptionApproximately 50% of new Revuforj patients in the quarter were estimated to have NPM1 disease. NPM1 patients accounted for more than 35% of Revuforj net revenue, compared with more than 30% in the prior quarter. Claims data showed approximately 75% of use in the second- and third-line settings and approximately 40% of use in combination therapy.
- Transplant and Post-Transplant Treatment TrendsRecent claims data indicated that approximately 40% of NPM1 patients treated with Revuforj proceeded to transplant, with approximately 50% resuming therapy afterward. Approximately 50% of KMT2A patients proceeded to transplant, with approximately 60% resuming therapy afterward, up from about 50% in the prior quarter. Management said 70% to 80% of KMT2A patients could ultimately return to therapy for 1 to 2 years based on physician feedback and clinical and real-world experience.
- Durable Revuforj Treatment DurationPatients receiving Revuforj in the post-transplant setting were averaging at least 9 months of therapy, and patients who did not receive a transplant but remained on treatment had an average treatment duration of more than 7 months. Management expects the post-transplant population to continue building and to drive longer average treatment duration. The company said the greatest impact from this trend is expected in 2027.
- Broadening Revuforj Commercial Footprint and AccessMore than 620 accounts had ordered Revuforj, up approximately 8% from the prior quarter. More than 90% of Tier 1 and Tier 2 accounts had ordered, compared with 70% before the NPM1 approval. Adoption continued across centers of all sizes, including community practices, and formulary coverage was in place for nearly 100% of covered lives for both indications. Management also reported high repeat prescribing among accounts.
- Clinical Recognition for RevuforjRevuforj received the Best Product for Rare Orphan Diseases Award from the Galien Foundation and was recognized by TIME as one of the best inventions of 2026. Management said these awards reflected the company's leadership in menin inhibition and the medicine's impact on patients with aggressive acute leukemias.
- Revuforj Development and Commercial Expansion OpportunitiesThe company expects new Revuforj data at the December ASH meeting across front-line combinations, transplant and post-transplant treatment, MRD-positive disease, and real-world studies. Management expects Revuforj could exceed $2 billion in peak annual U.S. net revenue with anticipated front-line indications. The company also expects to publish fourth-quarter data in relapsed/refractory NUP98-rearranged acute leukemia, a population estimated to represent approximately 2% to 5% of AML cases with no approved targeted treatment.
- Positive Revuforj Response and Front-Line EvidenceApproximately 1 out of 2 NPM1 patients achieved an overall response in the pivotal Revuforj trial. Previously reported front-line BEAT AML and SAVE data showed overall response rates approaching 90% and 100% MRD negativity among responders by flow cytometry, along with encouraging early survival data. The company expects longer follow-up and larger cohorts in the upcoming updates.
- Niktimvo Revenue and Market Penetration GrowthNiktimvo net revenue totaled $67 million, up 47% year-over-year and 12% quarter-over-quarter. More than 300 new patients were added and approximately 6,350 infusions were administered. The company reported capturing about one-third of the third-line-plus chronic GVHD market, with strong fourth-line adoption and steadily increasing third-line uptake.
- Niktimvo Contribution to ProfitabilitySyndax's 50% share of Niktimvo net profit generated $22.6 million of collaboration revenue, described as a meaningful contribution to the bottom line. Collaboration revenue was annualizing at more than $90 million, while Niktimvo sales were annualizing at more than $260 million. The company expects continued growth as it penetrates third- and fourth-line chronic GVHD.
- Niktimvo Front-Line Opportunity and Dosing DataTwo ongoing trials of Niktimvo in newly diagnosed chronic GVHD could impact the front-line treatment paradigm and unlock another multibillion-dollar opportunity. AGAVE-201 data showed that transitioning axatilimab from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks was feasible and well tolerated; median treatment duration after the switch was 21 months and 84% of patients remained on treatment at data cutoff.
- Pipeline Expansion and Upcoming Clinical MilestonesThe company expects its mutant-selective, allosteric EGFR inhibitor SNDX-4321 for EGFR-mutated non-small cell lung cancer and next-generation menin inhibitor SNDX-62122 for myelofibrosis to enter the clinic next year. Syndax remains on track to submit the 4321 IND by the end of 2026 and the 62122 IND next year. A Phase I/II proof-of-principle trial of revumenib in myelofibrosis is expected to initiate in the fourth quarter of 2026, with initial data anticipated in the second half of next year.
- Financial Position Supports Commercial and R&D PlansSyndax ended the quarter with $551 million in cash, cash equivalents and investments. Management said the company is fully funded to execute its commercial priorities, front-line revumenib trials, axatilimab trials and earlier pipeline programs. The 2026 guidance for total R&D plus SG&A expenses remains approximately $400 million, excluding $50 million of estimated noncash stock compensation expense.
- Improved Niktimvo Margin ContributionNiktimvo's margin contribution was approximately 34% of Niktimvo net sales in the quarter. Excluding the effect of a one-time, nonrecurring adjustment, management expects the margin contribution to be in the low-to-mid-30% range going forward, compared with the previously guided 25% to 30% range.
- Successful CFO Transition PlanKeith Goldan announced his retirement after more than 4 years at Syndax and more than 30 years in the biopharmaceutical industry. Aaron Ondrey is scheduled to become CFO effective November 9, bringing financial, operational, corporate strategy and commercialization experience in biopharmaceutical companies.
DE:1T3 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | -0.44- | -0.71 | ― | ― |
| Nov 02, 2026 | 2026 (Q3) | -0.46-0.50 | -0.64 | 21.43% (+0.14) | |
| Aug 04, 2026 | 2026 (Q2) | -0.41-0.50 | -0.76 | 33.73% (+0.26) | |
| Apr 30, 2026 | 2026 (Q1) | -0.55-0.44 | -0.89 | 51.02% (+0.46) | |
| Feb 26, 2026 | 2025 (Q4) | -0.53-0.71 | -1 | 29.09% (+0.29) | |
| Nov 03, 2025 | 2025 (Q3) | -0.66-0.64 | -0.89 | 28.57% (+0.26) | |
| Aug 04, 2025 | 2025 (Q2) | -0.93-0.76 | -0.73 | -3.75% (-0.03) | |
| May 05, 2025 | 2025 (Q1) | -1.14-0.89 | -0.78 | -15.29% (-0.12) | |
| Mar 03, 2025 | 2024 (Q4) | -0.77-1.00 | -0.91 | -10.00% (-0.09) | |
| Nov 05, 2024 | 2024 (Q3) | -0.98-0.89 | -0.67 | -34.25% (-0.23) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


